NZ203934A - Cancer treating compositions containing extracts from plants of hypoxidaceae family - Google Patents
Cancer treating compositions containing extracts from plants of hypoxidaceae familyInfo
- Publication number
- NZ203934A NZ203934A NZ203934A NZ20393483A NZ203934A NZ 203934 A NZ203934 A NZ 203934A NZ 203934 A NZ203934 A NZ 203934A NZ 20393483 A NZ20393483 A NZ 20393483A NZ 203934 A NZ203934 A NZ 203934A
- Authority
- NZ
- New Zealand
- Prior art keywords
- plant
- extract
- treatment
- hypoxis
- obtusa
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 241000196324 Embryophyta Species 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 241000234275 Hypoxidaceae Species 0.000 title claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 title claims description 12
- 201000011510 cancer Diseases 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 241000756171 Hypoxis Species 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 5
- 241000605417 Spiloxene Species 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 5
- 241001656007 Hypoxis hemerocallidea Species 0.000 claims description 3
- 241000841728 Pauridia affinis Species 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 241000214515 Heliconia acuminata Species 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 240000006760 Holboellia latifolia Species 0.000 claims 2
- 241000008285 Aquaspirillum soli Species 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010027463 Metastases to pleura Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 108700001232 mouse P Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Branching, Merging, And Special Transfer Between Conveyors (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8211294 | 1982-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ203934A true NZ203934A (en) | 1986-04-11 |
Family
ID=10529779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ203934A NZ203934A (en) | 1982-04-19 | 1983-04-19 | Cancer treating compositions containing extracts from plants of hypoxidaceae family |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4652636A (OSRAM) |
| EP (1) | EP0092226B1 (OSRAM) |
| JP (1) | JPS5916828A (OSRAM) |
| KR (1) | KR840004361A (OSRAM) |
| AT (1) | ATE29033T1 (OSRAM) |
| AU (1) | AU551625B2 (OSRAM) |
| CA (1) | CA1209912A (OSRAM) |
| CZ (1) | CZ278542B6 (OSRAM) |
| DE (2) | DE3373099D1 (OSRAM) |
| DK (1) | DK159377C (OSRAM) |
| ES (1) | ES8406501A1 (OSRAM) |
| GR (1) | GR78195B (OSRAM) |
| HU (1) | HU187039B (OSRAM) |
| IE (1) | IE54837B1 (OSRAM) |
| IL (1) | IL68471A0 (OSRAM) |
| IN (1) | IN159319B (OSRAM) |
| MX (1) | MX7295E (OSRAM) |
| NO (1) | NO163167C (OSRAM) |
| NZ (1) | NZ203934A (OSRAM) |
| PT (1) | PT76568B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317850D0 (en) * | 1983-06-30 | 1983-08-03 | Roecar Holdings Nv | Rooperol and its derivatives |
| US5609874A (en) * | 1992-09-07 | 1997-03-11 | Virostat (Na) Nvq | Method of treating viral infections |
| US5569649A (en) * | 1994-06-14 | 1996-10-29 | Phytopharm (Na) N.V. | Anti-inflammatory treatment method |
| US5958104A (en) * | 1997-09-11 | 1999-09-28 | Nonomura; Arthur M. | Methods and compositions for enhancing plant growth |
| WO2011110190A1 (en) | 2010-03-08 | 2011-09-15 | Romina Znoj | A cellobiose compound from herbal extracts having apoptotic activity |
| CN109704926B (zh) * | 2019-01-29 | 2022-02-08 | 南京工业大学 | 抗癌活性分子骨架1,4-烯炔类化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1259503A (OSRAM) | 1969-04-02 | 1972-01-05 | ||
| ZA721855B (en) | 1972-03-17 | 1973-05-30 | Liebenberg R W | Extraction of sterolins from plant material |
| DE2251695A1 (de) * | 1972-10-21 | 1974-04-25 | Reisch Johannes | Wirkstoffextrakt aus hypoxis spezies und verfahren zu seiner gewinnung |
| DE2759171A1 (de) | 1977-12-31 | 1979-07-12 | Roecar Holdings Nv | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor |
-
1983
- 1983-04-18 CA CA000426101A patent/CA1209912A/en not_active Expired
- 1983-04-18 IE IE865/83A patent/IE54837B1/en not_active IP Right Cessation
- 1983-04-19 KR KR1019830001699A patent/KR840004361A/ko not_active Ceased
- 1983-04-19 AT AT83103765T patent/ATE29033T1/de not_active IP Right Cessation
- 1983-04-19 NZ NZ203934A patent/NZ203934A/en unknown
- 1983-04-19 GR GR71129A patent/GR78195B/el unknown
- 1983-04-19 DK DK171883A patent/DK159377C/da not_active IP Right Cessation
- 1983-04-19 HU HU831359A patent/HU187039B/hu not_active IP Right Cessation
- 1983-04-19 IN IN256/DEL/83A patent/IN159319B/en unknown
- 1983-04-19 DE DE8383103765T patent/DE3373099D1/de not_active Expired
- 1983-04-19 PT PT76568A patent/PT76568B/pt not_active IP Right Cessation
- 1983-04-19 JP JP58069060A patent/JPS5916828A/ja active Granted
- 1983-04-19 EP EP83103765A patent/EP0092226B1/en not_active Expired
- 1983-04-19 DE DE198383103765T patent/DE92226T1/de active Pending
- 1983-04-19 CZ CS832776A patent/CZ278542B6/cs unknown
- 1983-04-19 NO NO831382A patent/NO163167C/no unknown
- 1983-04-19 AU AU13635/83A patent/AU551625B2/en not_active Ceased
- 1983-04-19 ES ES521634A patent/ES8406501A1/es not_active Expired
- 1983-04-19 MX MX8310588U patent/MX7295E/es unknown
- 1983-04-22 IL IL68471A patent/IL68471A0/xx not_active IP Right Cessation
-
1985
- 1985-05-02 US US06/729,683 patent/US4652636A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IN159319B (OSRAM) | 1987-05-02 |
| DK159377C (da) | 1991-03-18 |
| NO831382L (no) | 1983-10-20 |
| ES521634A0 (es) | 1984-07-16 |
| ES8406501A1 (es) | 1984-07-16 |
| JPS5916828A (ja) | 1984-01-28 |
| JPH0450292B2 (OSRAM) | 1992-08-13 |
| MX7295E (es) | 1988-04-25 |
| PT76568A (en) | 1983-05-01 |
| CA1209912A (en) | 1986-08-19 |
| DK171883D0 (da) | 1983-04-19 |
| CZ277683A3 (en) | 1993-08-11 |
| PT76568B (en) | 1986-04-17 |
| ATE29033T1 (de) | 1987-09-15 |
| NO163167B (no) | 1990-01-08 |
| EP0092226A2 (en) | 1983-10-26 |
| AU1363583A (en) | 1983-10-27 |
| HU187039B (en) | 1985-10-28 |
| NO163167C (no) | 1990-04-18 |
| EP0092226B1 (en) | 1987-08-19 |
| CZ278542B6 (en) | 1994-03-16 |
| IE830865L (en) | 1983-10-19 |
| DK159377B (da) | 1990-10-08 |
| AU551625B2 (en) | 1986-05-08 |
| KR840004361A (ko) | 1984-10-15 |
| DE92226T1 (de) | 1984-08-30 |
| EP0092226A3 (en) | 1984-01-04 |
| GR78195B (OSRAM) | 1984-09-26 |
| DE3373099D1 (en) | 1987-09-24 |
| DK171883A (da) | 1983-10-20 |
| IE54837B1 (en) | 1990-02-28 |
| US4652636A (en) | 1987-03-24 |
| IL68471A0 (en) | 1983-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100272835B1 (ko) | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 | |
| EP0092226B1 (en) | Extract of plants of the family of hypoxidaceae for treatment of cancer | |
| EP3569240A1 (en) | Composition for preventing or treating gastritis or peptic ulcer | |
| Ajibade et al. | Histopathological and toxicological effects of crude saponin extract from Phyllanthus niruri, L (Syn. P. franternus. Webster) on organs in animal studies | |
| KR101679391B1 (ko) | 피뿌리풀 추출물 또는 그의 분획물을 포함하는 상처를 치료하기 위한 조성물 및 개체의 상처를 치료하는 방법 | |
| DE3603227C2 (OSRAM) | ||
| CN108210493B (zh) | 用于改善胃癌前病变的药物组合物及其制剂 | |
| US20110165262A1 (en) | Reducing drug dependence or addiction | |
| CN121270664B (zh) | 一种多肽及其在治疗胃溃疡中的应用 | |
| KR20000019869A (ko) | 홍화자 추출물을 포함하는 경조직 재생촉진제 조성물 | |
| KR0161145B1 (ko) | 분방기 추출물을 함유하는 인터루킨-6 생산 억제용 조성물 | |
| KR100541248B1 (ko) | 암전이 억제효과를 갖는 장생도라지 추출물 | |
| KR20190025168A (ko) | 목진피 추출물을 유효성분으로 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물 | |
| KR20130067037A (ko) | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 암의 예방 또는 치료용 조성물 | |
| KR20040036092A (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
| KR100513125B1 (ko) | 장생도라지 추출물을 유효성분으로 포함하는 간장의항섬유화제 | |
| JPS6016926B2 (ja) | 医薬組成物 | |
| KR101305090B1 (ko) | 관절용 초본 제제 | |
| KR20040079742A (ko) | 종양괴사인자 알파와 인터루킨 8 분비 억제 및 비만세포이동 억제 효과를 이용한 염증성 질환 치료 및프로테오글라이칸, 글라이코아미노글라이칸, 콜라겐의생성을 촉진하여 무릎관절강 협착을 예방하고개선하는식품 조성물의 제조 방법 | |
| JP2007291014A (ja) | カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物 | |
| KR101085082B1 (ko) | 백지 추출물을 유효성분으로 함유하는 척수 손상 치료용 조성물 | |
| KR20000019867A (ko) | 골쇄보 추출물을 포함하는 경조직 재생촉진제 조성물 | |
| KR20000019865A (ko) | 우슬 추출물을 포함하는 경조직 재생촉진제 조성물 | |
| JPS60105627A (ja) | 抗腫瘍剤 | |
| UA142427U (uk) | Одержання рослинної субстанції з відхаркувальною активністю |